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Abstract
Background:  The application of high throughput molecular techniques such as SEREX are
resulting in the identification of a multitude of tumor associated antigens. As newly identified
antigens are incorporated into a variety of clinical trials, standardization of immunologic monitoring
methods becomes increasingly important. We questioned whether mammalian cell expression of
a histadine-linked human protein could be used to produce antigen suitable for detecting tumor-
specific humoral immunity and whether such an assay could be amenable to standardization for
clinical use.
Methods: We designed a his-tagged capture ELISA based on lysate from genetically engineered
CHO cells for detection of antibodies to insulin-like growth factor binding protein 2, a novel tumor
antigen. We performed technical and preliminary clinical validation studies, including comparison
to a standard indirect ELISA based on commercially prepared recombinant antigen.
Results: The his-tagged capture ELISA could be standardized. Precision experiments resulted in
CVs < 15%. Linearity and calibration experiments demonstrated r2 values of 0.99. In comparison
to Western blot analysis, his-tag and indirect ELISA accurately identified 88% and 93% of samples,
respectively. Sample concordance between capture and indirect assays was highly significant (p =
0.003). Furthermore, significantly greater levels of IGFBP-2 antibody immunity were found in
cancer patients compared to normal controls (p = 0.008).
Conclusion: A genetically engineered cell lysate based ELISA can be amenable to standardization
and can detect increased levels of antibody immunity to tumor-associated antigen in cancer patients
compared to non tumor-bearing healthy controls.
Background
Applications of high-throughput molecular techniques
are resulting in the identification of a multitude of tumor
associated antigens. Genomic and proteomic technolo-
gies have allowed immunogenic proteins to be deter-
mined for a wide variety of cancers. Both approaches
utilize humoral immune responses to screen for tumor-
associated antigens. Serological analysis of recombinant
cDNA expression libraries has led to the identification of
hundreds of cancer-specific antigens using sera from can-
cer patients to probe proteins encoded by tumor cDNA
libraries. Several of the proteins identified by this tech-
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nique have proven specific enough, and immunogenic
enough, to be incorporated into tumor vaccines currently
in clinical trials [1,2].
Specificity and immunogenicity of the many candidate
vaccine antigens identified must be comprehensively
characterized through population-based and laboratory
studies prior to initiation of clinical trials. The quality of
assays used for this purpose must meet standards man-
dated by the Clinical Laboratory Improvement Act (CLIA)
in order to make assessment of clinical trials meaningful
and to allow for comparison between trials conducted by
different groups. High-throughput, rapid screening assays
generally rely on commercially prepared and quality-con-
trolled proteins. However, many newly identified tumor-
associated antigens are not commercially available, and
due to expense, limited demand, and difficulties involved
in mass production of purified product, may not be pro-
duced outside the research lab. Given the need for both
high quality and flexibility in assay methods, we ques-
tioned whether his-tagged capture ELISA could be utilized
for evaluating antibody immunity against novel antigens.
If such an assay could be optimized to meet clinical labo-
ratory standards, it could serve as a template method for
use with potentially any cDNA of interest.
The hexahistadine tagging of recombinant protein
expressed in a transfected cell line offers several important
advantages to the development of antibody screening
assays. The method is relatively inexpensive compared to
preparation of recombinant protein. Moreover, post
translational modification necessary for immune recogni-
tion is maintained by choosing a eukaryotic cell line for
protein expression.
We have recently established insulin-like growth factor
binding protein (IGFBP-2) as a human tumor antigen
found at elevated levels in colon and breast cancer
patients [3], and in colon cancer patients IGFBP-2 overex-
pression is highly correlated with metastases and recur-
rence [4]. Furthermore, overexpression of the IGFBP-2
gene is associated with multi-drug resistance in human
colon carcinoma cell lines [5]. As recombinant IGFBP-2
protein is commercially available, the antigen serves as a
unique model in which to determine the clinical utility of
his-tagged ELISA.
Methods
Subjects
Serum from 80 breast cancer patients and 80 colorectal
cancer patients of any stage of disease and either sex was
obtained after IRB approval and informed consent for the
analysis of immunity against cancer. Patients had to be
greater than 30 days from the last cytoreductive chemo-
therapy. Age range of the patient group was 36–91 years.
The reference population sera was derived from non-can-
cer bearing volunteers, n = 200, contributing blood prod-
ucts at the Puget Sound Blood Center, Seattle, WA,
aliquoted into 200 ul fractions, and stored at -70°C. Indi-
viduals contributing the sera samples met all the health
requirements associated with blood donation. Age range
of the serologic control group was 18–72 years, 106 sam-
ples were from men and 94 samples were from women.
Vector construction and CHO cell transfection
The vector containing the cDNA for IGFBP-2 (a gift from
Dr. S. Plymate, University of Washington) and the
pcDNA4/HisMax B (Invitrogen, Carlsbad, CA) vector con-
taining the histadine tag and Zeocin resistance gene were
cut by digest with EcoRI and NotI. The full-length coding
sequence was ligated in frame to the HisMax B vector
according to commercial protocol (Invitrogen). Briefly,
0.5 ul HisMax B vector, 26 ul IGFBP-2 insert, 0.5 ul 2×
Ligation Master Mix (Qiagen, Valencia, CA), and 3 ul dis-
tilled H2O were mixed and incubated at 16°C for 2 hours.
The ligation/reaction mixture was stored at -20°C. The
coding region was confirmed by DNA sequencing.
The HisMax construct containing IGFBP-2 was then used
to transfect CHO cells as described below. CHO cells were
prepared for transfection by seeding 6-well plates with 0.5
× 106 CHO cells/well in RPMI with 10% FCS and incu-
bated at 37°C in 5% CO2 overnight. Cells were then
washed and 1.5 ml of media was added to each well.
Two ug of the HisMax B/IGFBP-2 vector were diluted with
EC buffer (Qiagen) to a total volume of 100 ul. The
diluted vector was then vortexed for 1 second and incu-
bated at room temperature for 5 minutes after addition of
32 ul of Enhancer (Qiagen). Ten ul of Effectene Transfec-
tion Reagent (Qiagen) was added to the DNA mixture and
mixed by vortexing, and incubated at room temperature
for 10 minutes. After addition of 0.5 ml media to the DNA
mixture, the DNA mixture was added to the plated cells by
pipetting up and down. Plates were then incubated at
37°C in 5% CO2 for 2 days. Cells were transferred to flasks
and kept in culture in RPMI 10% FCS to which 150 ug/ml
Zeocin (InvivoGen, San Diego, CA) was added as selec-
tion agent. As a control, another plate of cells was identi-
cally transfected with the pcDNA4/HisMax C vector
without the IGFBP-2 insert.
Preparation of cell lysate as source of protein
Cells transfected with the his-tagged IGFBP-2 or the
tagged mock-insert (His-B) were harvested at log-phase
growth by scraping. Cells were centrifuged and kept at -
70°C until sufficient cells had accumulated to prepare 50
ml of lysate. Cells were then thawed and incubated in
lysate buffer consisting of Tris base, NaCl and Triton-X,
with aprotinin (1 ug/ml), benzamidine (1 mmol/L) andBMC Immunology 2008, 9:23 http://www.biomedcentral.com/1471-2172/9/23
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phenylmethylsulfonyl fluoride (1 mmol/mL) added.
Cells were added to lysis buffer at a 108 cells/ml buffer
concentration, kept on ice and vortexed every 10 minutes
for 1 hour. Cells were then centrifuged for 20 minutes at -
20°C, supernatant was collected, aliquoted, and stored at
-70°C. The protein content of each lot of supernatant was
quantified (BioRad colorimetric Protein Assay kit #500-
0116), and protein identity confirmed for each lot by
Western blot analysis using a goat polyclonal anti-IGFBP-
2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) as
primary antibody and rabbit anti-goat-HRP conjugate
(Zymed, S. San Francisco) as secondary antibody. We used
a low molecular weight ladder (BioRad, Hercules, CA)
and a sample of human recombinant IGFBP-2 (Research
Diagnostics, Inc, Flanders, NJ) as positive controls and a
sample of the mock-transfected CHO lysate as a negative
control. Protein was immunoprecipitated by adding
mouse monoclonal anti-IGFBP-2 antibody (Diagnostic
Systems Laboratories, Webster, TX) to IGFBP-2/His-B cell
lysate with Protein A+G and allowing incubation over-
night at 4°C. The lysate was then vortexed and the pellet
washed twice with NNET buffer and twice with NET
buffer. SDS-PAGE running buffer was added after the last
wash, and the pellet was stored at -4°C.
Another immunoprecipitation was prepared with patient
serum by adding Protein G to IGFBP-2/His-B cell lysate
and incubating on ice for 5 minutes, vortexing several
times. The supernatant was collected and incubated over-
night at 4°C after the addition of Protein A+G and patient
serum positive by ELISA for IGFBP-2 antibodies. The pel-
let was prepared as described above.
Development of ELISA with protein derived from 
engineered CHO lysate
Microtiter plates (Dynex Technologies, Inc., Chantilly,
VA) were coated overnight with his-tag specific mono-
clonal antibody (Qiagen) diluted 1/1000 in carbonate
buffer. Only Immulon 4 HBX plates from a single lot were
used throughout the validation. The standard curve was
prepared by adding purified human IgG titrated to range
from 0.62 ug/ml to 0.005 ug/ml, 50 ul/well, to the last
column. All IgG for the standard curves was aliquoted
from the same vial to assure consistency between curves.
Plates were blocked with 100 ul PBS/5% BSA for 8 hours
at room temperature, washed 4 times with PBS/0.01%
tween-20 and alternating columns coated with 50 ul
IGFBP-2 lysate diluted to 80 ug/ml in PBS/BSA, the mock
vector, or PBS/BSA buffer alone. Plates were then incu-
bated overnight at 4°C. Following 4 washes with PBS/
Tween, patient sera was added after dilution with 10%
NGS/10% FCS/PBS/1% BSA/25 1:25 through 1:200 and
incubated 2 hours at room temperature. Plates were
washed and goat IgG-HRP conjugate (Zymed Laborato-
ries, San Francisco, CA) diluted 1:50,000 in PBS/BSA
buffer, 50 ul/well, was added and incubated for 45 min-
utes at room temperature. Plates were washed 4 times and
developed with 75 ul TMB reagent (Kirkegaard and Perry
Laboratories, Gaithersburg, MD) and read at 640 nm.
Reaction was stopped with 75 ul 1 N HCL when the 0.16
μg/ml standard reached an OD of 0.3, and plates were
read at 450 nm. The OD of each serum dilution was cal-
culated as the OD of the lysate-coated wells minus the OD
of the His B-coated wells.
Positive control serum was run on every plate, as was a
negative control of PBS/BSA buffer treated as a serum sam-
ple. Results for the IGFBP-2 antibody capture ELISA assay
were confirmed by Western blot analysis. Samples were
designated positive by ELISA based on a non-parametric
95th percentile cut-point obtained by running 200 normal
control samples through the assay. Positive cut-point for
the capture assay was 0.18 ug/ml (0.024+/-0.051).
Development of ELISA with purified recombinant IGFBP-2
In order to address the issue of anti-histidine or anti-
nickel interference in the capture assay, to and compare
capture assay results to the gold standard ELISA, we devel-
oped an indirect ELISA for IGFBP-2 antibodies. Immulon
4HBX microtiter plates (Dynex), were coated overnight
with 50 ul of highly purified, human recombinant IGFBP-
2 protein (Sigma Chemical Co. St. Louis, MO) diluted 1/
1000 with carbonate buffer to a concentration of 0.5 ug/
ml, or carbonate buffer alone in alternating columns. The
last column of wells was incubated with serially diluted,
purified human IgG (Sigma) to provide a standard curve.
Plates were blocked with 100 ul 1% BSA/PBS at room
temperature for 1 hour, washed 4 times with PBS/Tween-
20 and coated with experimental serum titrated as above.
Plates were incubated for 1 hour at room temperature,
washed 4 times and incubated for 45 minutes at room
temperature after addition of 50 ul IgG-HRP conjugate
(Zymed). Plates were washed, TMB was added and plates
were developed and read as above. The OD of each serum
dilution was calculated as the OD of the protein-coated
wells minus the OD of the buffer-coated wells. Values for
ug/ml were calculated from the standard curve on each
plate, and positive cut-point for the indirect ELISA was set
at 0.5 ug/ml (0.026+/-0.148).
Assay validation
Standardization and validation of the capture ELISA was
conducted as previously reported [6]. Briefly, accuracy was
determined by assay of purified human IgG, diluted to 8
aliquots ranging from 0.62 μg/ml to .00025 μg/ml. The
mean and CV for each concentration was compared to the
expected value using regression analysis. The resulting r2
value was used to quantify accuracy. Precision was deter-
mined by evaluating positive control samples in sets of 20BMC Immunology 2008, 9:23 http://www.biomedcentral.com/1471-2172/9/23
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replicates. The 20 replicates were assayed together during
one run to obtain the CV value for quantifying intra-assay
precision. The 20 replicates were aliquoted, kept frozen
and assayed individually during 20 separate runs over 6
weeks to obtain the CV value for quantifying interassay
precision. Linearity and range were established by
repeated assay of serially diluted positive samples, and
quantified by the r2 from regression analysis of expected
versus resulting value. Sensitivity and specificity were
determined by Chi2 comparison of ELISA-positive and
negative samples to the same samples assessed for IGFBP-
2 antibodies by Western blot. A population of 200 normal
donors, 80 breast and 80 colorectal cancer patients was
evaluated to determine the ability of the capture assay to
discriminate between tumor bearing and non-tumor bear-
ing individuals.
Statistical Analysis
All data were analyzed using SPSS 13.0 for Windows
(SPSS Inc, Chicago, IL). Validation standards in linearity,
range and accuracy were assessed by linear regression. Val-
idation standards in sensitivity and specificity were
assessed by Chi2 table of Western blot and dichotomized
ELISA results. Differences in response to the mock vector
were assessed by t-test. Presence of antibodies in patients
and normal controls was analyzed by Chi2 test, and mag-
nitude of antibody responses was evaluated by Kruskal-
Wallis and Mann-Whitney U test where appropriate. The
relationship between sample results from the indirect
assay and the capture assay was investigated by Pearson's
product-moment correlation. Receiver operating charac-
teristic (ROC) curves were constructed as a preliminary
investigation of capture ELISA discriminatory capacity,
and the area under the curve analyzed by Chi2 test. All sta-
tistical tests were 2-tailed and corrected for multiple com-
parisons by Bonferroni adjustment where appropriate.
Results
Capture ELISA for measurement of antibody response to 
his-tagged tumor-associated antigen can be developed to 
meet clinical validation standards in linearity and precision
The standard required of a calibration curve for a clinical
laboratory assay is an r2 value of no less than 0.95, with a
mean CV for replicate samples no greater than 15%. Vali-
dation of a lysate-based capture ELISA has been previously
described in detail [6]. Similar calibration experiments
showed that the mean CV for replicate samples (n= 20)
measured by the IGFBP-2 capture ELISA was 8% and the
r2 for the assay was 0.99 (y = 0.001 + 0.815x, Sy/x = 0.001).
Sample linearity was also assessed with a resulting r2 of
0.99 (y = 1.627 - 0.057x, Sy/x = 0.025). Precision character-
istics for the assay were established for single plate, single
run (intra-assay) and between multiple runs (interassay).
The capture assay of 20 positive replicates on a single plate
yielded a mean of 1.16 ug/ml and CV of 13%. Multiple
run precision was established over 20 consecutive experi-
ments and returned a mean of 2.21 ug/ml and CV of 14%,
below the standard maximum of 15% (Fig. 1A).
Capture ELISA for measurement of antibody response to his- tagged tumor-associated antigen can be developed to meet  standard requirements in precision, and there is no significant  difference in antibody response to the his-tagged mock vec- tor between normal donors or cancer patients Figure 1
Capture ELISA for measurement of antibody 
response to his-tagged tumor-associated antigen can 
be developed to meet standard requirements in pre-
cision, and there is no significant difference in anti-
body response to the his-tagged mock vector 
between normal donors or cancer patients. (A) 
Twenty replicates of a sample positive for antibodies to 
IGFBP-2 were analyzed by capture ELISA to determine intra-
assay precision (closed boxes) and interassay precision (open 
boxes). Data is expressed as IGFBP-2 IgG in ug/ml. (B) 
Response to the CHO cell lysate transfected with the his-
tagged mock vector was assayed by capture ELISA for nor-
mal controls and cancer patients. Data is expressed as OD; 
bars represent mean OD for each group.
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There is no significant difference in antibody response to 
the his-tagged mock vector between controls and cancer 
patients
To address the possibility of differences in response to the
empty vector between cancer patients and normal con-
trols, we assayed 20 non-cancer bearing volunteers and 20
cancer patients by capture ELISA with the empty vector
and compared the resulting mean optical densities. The
Kolmogorov-Smirnov test for normality indicated approx-
imately normal distribution, and the t-test found no sig-
nificant difference (p = 0.770) between mean OD for the
cancer group (OD = 0.24+/-0.118) and mean OD for the
control group (OD = 0.24+/-0.159) (Fig. 1B).
Capture ELISA results confirmed by Western blot analysis
The cell lysate used as the capture ELISA antigen was
immunoprecipitated with a histadine specific antibody,
and the resulting immunoprecipitate run in Western blot
analysis against 6 patient samples which assayed positive
for IGFBP-2 antibodies by ELISA and 10 samples which
assayed negative for IGFBP-2 antibodies by ELISA (Fig
2A). Identical blots were performed using commercially
prepared recombinant human IGFBP-2 instead of the pre-
cipitated his tagged IGFBP-2 (Fig. 2B) in order to confirm
the identity of the antigen recognized by antibodies in
patient samples. A molecular weight ladder was run with
each blot, as was a commercial IGFBP-2 Western blot pos-
itive control. The His-B lysate was immunoprecipitated
with the histidine antibody and run as a negative control.
Comparison of capture ELISA results to Western blot
results for the same samples indicated that 88% of sam-
ples were correctly identified by ELISA. Thus, technical
specificity was 83% and technical sensitivity was 100%.
IGFBP-2 capture ELISA can discriminate between cancer 
patients and controls
Two hundred samples from healthy volunteers, 80 sam-
ples from breast cancer patients, and 80 samples from
colon cancer patients were assayed for antibodies to
IGFBP-2 using the capture ELISA. Magnitude of antibody
response was significantly increased in breast and colon
cancer patients compared to control samples (Fig. 3A) (p
< 0.001) when 3-way analysis of continuous data was per-
formed by Kruskal-Wallis test. Levels of IGFBP-2 antibod-
ies were increased in breast cancer patients compared to
normal volunteers (p = 0.013), and in colon cancer
patients compared to normal volunteers (p < 0.001) when
analyzed by Mann-Whitney U test. Continuous results
from all samples were dichotomized using the 0.18 ug/ml
cut-point derived from the reference range and subjected
to Chi2 test. The capture assay found that the presence of
antibodies to IGFBP-2 was significantly increased in the
population of cancer patient samples, where 23% of
patients were positive, compared to control samples, with
a positive rate of only 1% (p = 0.008). Furthermore, in
comparisons between controls and each type of cancer,
5% of breast cancer patients (p = 0.032) and 40% of color-
ectal cancer patients (p < 0.001) had IGFBP-2 specific
antibodies, compared to controls (Fig. 3B).
There is significant concordance between patient sample 
results determined by his-tag capture ELISA and standard 
indirect ELISA
We developed an indirect ELISA using commercially avail-
able recombinant human IGFBP-2. This assay meets all
clinical laboratory requirements and allows comparison
Results from capture ELISA are confirmed by Western blot  analysis Figure 2
Results from capture ELISA are confirmed by West-
ern blot analysis. (A) Representative example of a sample 
positive by capture ELISA analyzed by Western blot using 
IGFBP-2 lysate. Molecular weight (lanes 1&8), Western blot 
control (lanes 2&7), Immunoprecipitated IGFBP-2 lysate 
(lanes 3&6), and immunoprecipitated His-B lysate (lanes 
4&5). (B) The same sample is also positive by Western blot 
using recombinant IGFBP-2 protein instead of hist-tagged 
protein. Molecular weight (lanes 1&8), Western blot control 
(lanes 2&7), recombinant human IGFBP-2 (lanes 3&6), and 
immunoprecipitated His-B lysate (lanes 4&5).
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of a standard indirect ELISA with the his-tag-based capture
ELISA described here (Table 1). The relationship between
level of antibody response to the his-tagged IGBFP-2 pro-
tein by capture ELISA and level of antibody response by
indirect ELISA was measured using Pearson's product-
moment correlation (Fig. 4A). Matched results for all
patient samples measured by both assay methods (n = 80)
revealed a strong (r = 0.537), significant (p = 0.003) posi-
tive correlation. Preliminary assessment of the discrimina-
tory capability of the assay was represented by ROC
curves, and indicated that the capture ELISA is a weak pre-
dictor of presence of cancer with an area under the curve
of 0.643 +/- 0.034, significantly different from the area
expected by chance (p < 0.001) (Fig. 4B).
Discussion
Many new tumor antigens are being identified. There is a
need to develop rapid, accurate methods to assess immu-
nity to novel antigens in large numbers of samples. We
questioned whether a capture ELISA using engineered
protein could be constructed to be reproducible to clinical
standards. The use of tumor cell lysates as a source for
Correlation of patient sample results by capture ELISA and  indirect ELISA is significant Figure 4
Correlation of patient sample results by capture 
ELISA and indirect ELISA is significant. (A) Results 
from samples positive by indirect ELISA (horizontal axis) and 
capture ELISA (vertical axis) were plotted and the strength of 
the association between results using both methods was 
assessed by Pearson's product-moment correlation. Results 
are in ug/ml, and the best-fit line is shown for reference. (B) 
The ROC curve was constructed using results from normal 
donors and patients with breast or colon cancer and plotted 
as diagnostic sensitivity vs. 1- diagnostic specificity.
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The IGFBP-2 capture ELISA can discriminate between cancer  patients and controls Figure 3
The IGFBP-2 capture ELISA can discriminate 
between cancer patients and controls. (A) Data is 
expressed as IGFBP-2 IgG in ug/ml. Lines represent mean of 
antibody responses to IGFBP-2 by capture ELISA. (B) Bars 
represent percentage of samples positive for antibodies to 
IGFBP-2 by capture ELISA.
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antigen avoids many of the issues associated with devel-
oping high throughput assays for humoral immune mon-
itoring such as lack of commercially prepared proteins
and background responses to E. coli used in producing
recombinant proteins [7,8]. We have previously shown
that tumor cell lysate-based assays can be made CLIA-
ready and suitable for high-throughput use in the clinical
lab [6]. Data presented here demonstrates eukaryotic cell
lines engineered to express tumor antigens can be devel-
oped to meet clinical laboratory specificities. Clinical
grade his-tagged ELISA will greatly facilitate analysis of
cancer specific humoral immunity.
The use of human tumor cell lines as a source of protein
presents unique challenges. Mammalian cells, such as
human tumor cells, have complex nutritional and envi-
ronmental requirements compared to prokaryotic cells,
making the culture of these cells complex, costly and
prone to contamination. Lack of a cell wall, such as that
found in bacteria, makes human cell lines more vulnera-
ble to mechanical damage and may impact integrity of the
protein of interest. Furthermore, proteins may naturally
be expressed at only low levels in the cell. This may be rec-
tified by induction of increased expression via reagents or
equipment such as bioreactors or microcarriers [8], add-
ing to the complexity and expense of high-yield protein
production. In addition, high background responses asso-
ciated with human cells may prevent detection of mar-
ginal immune responses to tumor antigens. Unlike
responses to infectious disease antigens, antibodies to
tumor-associated proteins are likely to be modest in mag-
nitude and of lower affinity [9]. Most importantly, pro-
teins derived from tumor cells are necessarily limited to
those proteins found naturally in the cell line [10,11]. The
identification of a cell line which overexpresses a particu-
lar protein can be a laborious, time-consuming and
potentially an unsuccessful process.
With the widening availability of cDNA libraries and cur-
rent ease of cloning techniques, genes encoding proteins
of interest to tumor antigen discovery efforts are accessible
and easy to handle. The use of CHO cells and the hexahis-
tadine tag offers key advantages to the development of
tumor-associated antigen assays. Mammalian cell process-
ing preserves post-translational modification which has
been shown to be important to immune recognition
[8,10], and CHO cells, cultured in laboratories since the
early 1960s, have demonstrated the relatively rapid,
robust growth and relatively high protein expression
required. CHO cells have proven capable of producing
naturally-occurring proteins, transfected animal proteins
and human recombinant proteins [12,13].
Conclusion
Our experience with the IGFBP-2 transfected CHO line
demonstrates that the cells can be kept in culture for up to
3 years without loss of protein expression, and that quan-
tity and quality of the his-tagged protein remains consist-
ent over that time. The his-tagged antigen also provides a
means of purifying the protein during assay, eliminating
the need for extra purification steps with associated cost
and time. By coating ELISA plates with an anti-histadine
monoclonal antibody prior to application of protein, the
antigen presented to the experimental sample is limited to
the tagged protein, and assay background is significantly
reduced. By comparing the his-tagged protein to a highly
purified recombinant commercial protein, we were able
to demonstrate that presence of a histidine tag does not
stimulate a significant anti-his response in patients or nor-
mal controls. Furthermore, comparison to the purified
protein indicates no significant interference from anti-
nickel elements within samples, a possibility due to the
presence of nickel sensitivity in approximately 13% of
adults [14]. Methods for creating histadine tagged pro-
teins and cell transfection are easy, fast and commercially
available at modest cost. The method may potentially be
used with any human tumor-associated antigen gene.
With the advent of high throughput technologies for anti-
gen discovery we need high throughput methods for anti-
Table 1: Direct and his-tag ELISAs for IGFBP-2 antibodies meet validation standards.
Parameter evaluated Assay for antibodies to IGFBP2 Standard
Indirect His-tag
Limit of detection, ug/ml 0.0005 0.0005 N/A
Intra-assay cv 12% 13% <15%
Inter-assay cv 11% 14% <15%
Accuracy 93% 88%
(technical specificity) (91%) (83%) >90%
(technical sensitivity) (100%) (100%)
Calibration curve r2 = 0.99 r2 = 0.99 r2 = 0.95
cv = 7% cv = 8% cv <15%
Reference range, ug/ml 0.025+/-0.148 0.024+/-0.051 N/APublish with BioMed Central    and   every 
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gen evaluation. Success of the technique described here
indicates that a similar system may be used to obtain clin-
ical quality antigen specific for potentially any protein
within a cDNA library, and thus development of a high-
throughput, clinical grade assay is limited only by availa-
bility of the gene encoding the target protein.
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